SPTX compared with LYEL: revenue, margins and what each company keeps, and the suppliers and customers both name

SPTXSeaport Therapeutics, Inc.

Mkt capRevenueRevenue

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

Compare

SPTXSeaport Therapeutics, Inc.

LYELLyell Immunopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SPTX2 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+2.09%—

Q2 FY26—▲+0.93%—

LYEL1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±35.4%▲+3.52%×0.10

= impliedSPTX realized, solidLYEL realized, hatchedOne scale, both sides: full bar = 36%× = |realized| ÷ impliedSource: market data

SPTXSeaport Therapeutics, Inc.

19.73· pre 19.73· delayed

Mkt cap$1.1BRevenue—Revenue—

LYELLyell Immunopharma, Inc.

10.69· pre 10.69· delayed

Pre-marketNov 2 '26delayed

Mkt cap$270.5MRevenue$4,000Q2 FY26Revenue$36,000FY25

Compare

Pre-marketNov 2 '26delayed

SPTXSeaport Therapeutics, Inc.

LYELLyell Immunopharma, Inc.

19.73pre 19.73delayed

Price

10.69pre 10.69delayed

$1.1B

Mkt cap

$270.5M

—

Revenue

$4,000Q2 FY26

—

Revenue

$36,000FY25

SPTX19.73vsLYEL10.69Pre-marketNov 2 '26delayed